# OnCo record met-altered-nsclc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/met-altered-nsclc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "met-altered-nsclc" ;
  schema:name "MET exon 14 and MET-amplified non-small-cell lung cancer"@en ;
  schema:alternateName "MET exon 14 skipping lung cancer"@en, "METex14 NSCLC"@en, "MET-amplified lung cancer"@en, "c-Met overexpressing NSCLC"@en ;
  schema:description "MET-driven lung cancer comes in three forms: an exon 14 skipping mutation treated with the pills capmatinib or tepotinib, MET amplification that often arises as an escape route from EGFR drugs, and high c-Met protein levels that the antibody-drug conjugate telisotuzumab vedotin targets."@en ;
  schema:url <https://onco.cc/cancers/met-altered-nsclc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/C-Met> ;
  schema:citation <https://en.wikipedia.org/wiki/C-Met>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450> ;
  onco:tag "subtype-page", "lung" ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/met/>, <https://onco.cc/targets/egfr/> ;
  onco:drugs <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/crizotinib/> ;
  onco:companies <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/merck-kgaa/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/hengrui/> ;
  onco:pathways <https://onco.cc/pathways/nsclc-signalling/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:terms <https://onco.cc/terms/met-amplification/>, <https://onco.cc/terms/resistance/>, <https://onco.cc/terms/driver-mutation/>, <https://onco.cc/terms/tki-term/> ;
  onco:trials <https://onco.cc/trials/geometry-mono-1/>, <https://onco.cc/trials/nct02864992/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/trials/nct03778229/> ;
  onco:people <https://onco.cc/people/ross-camidge/>, <https://onco.cc/people/alexander-drilon/> ;
  onco:pipeline <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/drugs/amivantamab/> ;
  onco:standardOfCare <https://onco.cc/drugs/capmatinib/>, <https://onco.cc/trials/geometry-mono-1/>, <https://onco.cc/drugs/tepotinib/>, <https://onco.cc/trials/nct02864992/>, <https://onco.cc/drugs/capmatinib-tepotinib/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/savolitinib/>, <https://onco.cc/trials/nct03778229/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/trials/nct04988295/>, <https://onco.cc/terms/met-amplification/>, <https://onco.cc/drugs/telisotuzumab-vedotin/>, <https://onco.cc/trials/luminosity/>, <https://onco.cc/trials/telimet-nsclc-01/>, <https://onco.cc/drugs/docetaxel/> .